Important note
Checking the safety profile of our medicines helps us to take the appropriate action to improve the safety of our patients, manage any potential risks associated with the use of the medicine and protect public health.
By reporting the use of our medicines during pregnancy and/or breastfeeding, even if no side effect was experienced, you will help us monitor safe use of medicines at these special times. Pregnant/breastfeeding women should always consult their HCP before starting any medicines during pregnancy and/or breastfeeding.
If you wish to report a side effect related to the use of one of our products or if you are pregnant or breastfeeding while using one of our products, please talk to your doctor, pharmacist or nurse, or contact us by using the webform available here.
Our Mission and Vision
UCB’s mission is to empower women of childbearing age living with chronic diseases to make informed decisions about their healthcare. Our vision is to advance science in the care of these women, as we believe they should be protected through research – not from it.
Play our film below to hear from women discussing the importance of having reliable data, and open and honest conversations about family planning when living with a chronic disease.
▶ Watch 4:35
Family Planning with a Chronic Disease
Starting or expanding a family is exciting but can be a time of uncertainty if living with a chronic disease. No woman should have to choose between her health and her family, but many of you are confronted with confusing information about risks.
At UCB, we believe you can improve the health of both you and your child by managing your disease before, during, and after pregnancy.1,2 Frustratingly, choosing the best treatment while planning for a family is challenging due to insufficient information and data. Just 5% of medications are properly evaluated for use during pregnancy and breastfeeding.3
UCB’s mission is to close the research gaps
UCB’s mission is to close these research gaps affecting pregnancy and breastfeeding, to empower you and other women with chronic diseases like epilepsy or psoriasis to make informed health decisions.
Our work in this space began more than a decade ago and our mission to empower women with chronic diseases to make informed decisions about their healthcare is deeply rooted in our drug development.
We were one pioneer company to conduct clinical research and to generate strong evidence in women with chronic inflammatory diseases during pregnancy and breastfeeding.4 We design studies with women in mind. We want to protect you and close the research gap.
The following external resources provide further information and guidance for women living with chronic diseases:
Creating value through action
Read our latest stories
References
- Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795–810.
- Tomson T, Battino D, Bromley R, et al. Management of epilepsy in pregnancy: a report from the International League Against Epilepsy Task Force on Women and Pregnancy. Epileptic Disord. 2019;21(6):497–517.
- ConcePTION. Background. Available at: https://www.imi-conception.eu/background/. Last accessed: December 2024.
- Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77:228-33.